70922-35-9 Usage
Description
N-(2-PIPERIDIN-4-YL-ETHYL)-ACETAMIDE is a chemical compound with the molecular formula C10H18N2O. It is a derivative of the compound acetamide, with the addition of a piperidine group. This molecule is commonly used in pharmaceutical research and is considered to have potential therapeutic properties. The piperidine group is known for its bioactivity in various drugs and compounds, making N-(2-piperidin-4-yl-ethyl)-acetamide an interesting molecule for further study.
Used in Pharmaceutical Research:
N-(2-PIPERIDIN-4-YL-ETHYL)-ACETAMIDE is used as a research compound for its potential therapeutic properties. The addition of the piperidine group to the acetamide structure contributes to its bioactivity, making it a promising candidate for the development of new drugs and pharmaceuticals.
Used in Chemical Industry:
In the chemical industry, N-(2-PIPERIDIN-4-YL-ETHYL)-ACETAMIDE is used as a building block for the synthesis of more complex molecules with potential applications in various fields. Its unique structure and properties make it a valuable component in the creation of new chemical entities.
Check Digit Verification of cas no
The CAS Registry Mumber 70922-35-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,0,9,2 and 2 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 70922-35:
(7*7)+(6*0)+(5*9)+(4*2)+(3*2)+(2*3)+(1*5)=119
119 % 10 = 9
So 70922-35-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H18N2O/c1-8(12)11-7-4-9-2-5-10-6-3-9/h9-10H,2-7H2,1H3,(H,11,12)
70922-35-9Relevant articles and documents
Design and synthesis of thrombin inhibitors: Analogues of MD-805 with reduced stereogenicity and improved potency
Brundish, Derek,Bull, Alice,Donovan, Vera,Fullerton, Joseph D.,Garman, Sheila M.,Hayler, Judy F.,Janus, Diana,Kane, Peter D.,McDonnell, Mark,Smith, Garrick P.,Wakeford, Robert,Walker, Clive V.,Howarth, Graham,Hoyle, William,Allen, Mark C.,Ambler, John,Butler, Keith,Talbot, Mark D.
, p. 4584 - 4603 (2007/10/03)
Mitsubishi's MD-805, a potent and selective inhibitor of thrombin which contains four stereogenic centers, has been the starting point for an optimization program. A systematic synthetic study resulted in thrombin inhibitors achiral at P2 and P3 but with
